This is a working overview of TH9507, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-02 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
=== Prohormone supplements === The most everyday use of prohormones is as supplements for muscle growth via ergogenic and anabolic agents. Prohormone supplements became popular from 1960 to 2001 and became used unregulated in Major League Baseball before select prohormones such as androstenedione and androstenediol became banned in the United States' Anabolic Steroid Control Act of 2004. Many prohormone supplements that were claimed to impart anabolic or ergogenic effects in men were banned for their poor side effects, commonly in supplements such as in 3β-hydroxy-5α-androst-1-en-17-one, commonly known as 1-testosterone, which are as follows:
== Epidemiology == Fever is one of the most common medical signs. It is part of about 30% of healthcare visits by children, and occurs in up to 75% of adults who are seriously sick. About 5% of people who go to an emergency room have a fever.
== Bibliography == Elyse; Houde, Alain (2002). "La PCR en temps réel: principes et applications" (PDF). Reviews in Biology and Biotechnology. 2 (2): 2–11. Archived from the original (PDF) on 2009-06-12. Bustin, SA (2000). "Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays". J Mol Endocrinol. 25 (2): 169–193. doi:10.1677/jme.0.0250169. PMID 11013345. Higuchi, R.; Dollinger, G.; Walsh, P.S.; Griffith, R. (1992). "Simultaneous amplification and detection of specific DNA-sequences". Bio-Technology. 10 (4): 413–417. doi:10.1038/nbt0492-413. PMID 1368485. S2CID 1684150. Holland, P.M.; Abramson, R.D.; Watson, R.; Gelfand, D.H. (1991). "Detection of specific polymerase chain reaction product by utilizing the 50 !30 exonuclease activity of Thermus aquaticus DNA polymerase". Proc. Natl. Acad. Sci. USA. 88 (16): 7276–7280. Bibcode:1991PNAS...88.7276H. doi:10.1073/pnas.88.16.7276. JSTOR 2357665. PMC 52277. PMID 1871133. Kubista, M; Andrade, JM; Bengtsson, M; Forootan, A; Jonak, J; Lind, K; Sindelka, R; Sjoback, R; Sjogreen, B; Strombom, L; Stahlberg, A; Zoric, N (2006). "The real-time polymerase chain reaction". Mol. Aspects Med. 27 (2–3): 95–125. doi:10.1016/j.mam.2005.12.007. PMID 16460794. Higuchi, R.; Fockler, C.; Dollinger, G.; Watson, R. (1993). "Kinetic PCR: Real time monitoring of DNA amplification reactions". Biotechnology. 11 (9): 1026–1030. doi:10.1038/nbt0993-1026. PMID 7764001. S2CID 5714001. Filion, M. (2012). Quantitative Real-time PCR in Applied Microbiology. Caister Academic Press. ISBN 978-1-908230-01-0.
Squadron Leader Iain Roderic Gillespie (2618287), (Retired). Warrant Officer Anthony John Gough, , (N1944467). Corporal (now Acting Sergeant) Alistair Colin Green (B8213475). Warrant Officer Michael John Hatch (M0593513). Squadron Leader Mark William Gardner Hopkins (2625781). Warrant Officer William James Cameron Kearney, , (D1949781). Sergeant Gary Kennedy (L8001367). Sergeant Roy Martin (A8015128). Warrant Officer Brian David Medland (R1949361), (Retired). Corporal (now Acting Sergeant) Kevin John Mulloy (F8201300). Corporal Ian William Partington (T8153337). Squadron Leader Vivienne Alexandra Sim (2797569), (Retired). Warrant Officer Keith Alexander Smith (P8089172). Squadron Leader Steven Glynn Smyth (8025529). Warrant Officer Barry Walch (U4287360). Junior Technician Peter Allan Wildman (D8410829). Squadron Leader Timothy Andrew Wilkinson (5203138). Master Aircrew Alistair John Woolfson (T8018944). Civil Division Kenneth Elliott Ackerley. For services to Physically Handicapped People. Graham Clifford Adams, Storekeeper, Manufacturing Division, Rolls-Royce & Associates plc. For services to the Automobile Industry. William Aitken. For services to the community in Aberdeen. Anne Aldred, Revenue Assistant, Board of Inland Revenue. Richard John Alibone, Senior Professional Technical Officer, Foreign and Commonwealth Office. Lieutenant Commander Peter Douglas Allen, Royal Navy (Retd.), Retired Officer 2, Ministry of Defence. Yashwanti Chandrakant Amlani. For services to Community Relations in Bristol. Ann McCall Amos, Personal Secretary, Ministry of Defence.
Sources: en.wikipedia.org
About 21,000 were raised in the First World War, mainly consisting of Sikhs of Punjab and Rajputs from Rajputana (such as the Bikaner Camel Corps and the Hyderabad, Mysore and Jodhpur Lancers of the Imperial Service Cavalry Brigade). These forces played a prominent role in the Sinai and Palestine Campaign.
Females have bodies that are up to 30% larger than an adult male. Unlike humans, the sex and physical appearance of fruit flies is not influenced by hormones. The appearance and sex of fruit flies is determined only by genetic information.
====== Latin America ====== Drug war policies in Latin America and the Caribbean have led to more violence, higher incarceration rates, health crises, and deeper poverty, while undermining trust in institutions and worsening inequality. There is increasing support for shifting toward drug policies that focus on sustainable development and human rights instead of punitive measures.
Tanaka Team have developed a diagnostic technology that enables early detection of diseases from a small amount of blood. By artificially modifying antibodies with polyethylene glycol at their base, the arms can move like springs, allowing simultaneous binding to antigens. In experiments with protein fragments related to Alzheimer's disease, the modified antibodies captured antigens more than 100 times more strongly than conventional antibodies. Later improvements enabled glycan analysis from trace mixed samples without peptide selection, leading to the detection of Alzheimer’s-related proteins from 1 mL of blood and the identification of eight previously unknown related substances. This technology is expected to contribute to the early detection of various diseases, including Alzheimer’s disease and prostate cancer. The research originated from work awarded the Nobel Prize in 2002, though the initial methods lacked sufficient sensitivity for medical applications. In 2009, it was selected for the FIRST Program, Development of Next-Generation Mass Spectrometry Systems and Contributions to Drug Discovery and Diagnosis, which provided about 4 billion yen over five years. With a team of around 60 researchers, a breakthrough analytical method was developed within a year, achieving up to a 10,000-fold increase in sensitivity. In November 2011, the team described the results as a technology applicable to early diagnosis and antibody-based drug development, publishing findings in the electronic edition of an English journal issued by the Japan Academy.
Ideology, values or interests Applied, empirical or synthesis research Theoretical or academic research According to the National Institute for Research Advancement, a Japanese policy institute, think tanks are "one of the main policy actors in democratic societies ..., assuring a pluralistic, open and accountable process of policy analysis, research, decision-making and evaluation". A study in early 2009 found a total of 5,465 think tanks worldwide. Of that number, 1,777 were based in the United States and approximately 350 in Washington, DC, alone.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.